PRURISOL

Oral psoriasis drug candidate in a Phase 2b trial utilizing the advantages of 505(b)(2) development approach

KEVETRIN

Orphan-designated p53-modulating drug candidate starting a Phase 2a trial for late-state ovarian cancer  

BRILACIDIN

Member of a new antibiotic class with unique immunomodulatory properties granted Fast Track designations